The CANS-MCI -- an easy-to-use computer-assisted, touchscreen, cognitive test for MCI

Enhance your patient care.
Gain higher reimbursements with the CANS-MCI.

Experience the precision and accuracy of Screen, Inc’s leading-edge Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment

  • Tracking "Chemo Brain"

    When cognitive and emotional changes associated with cancer treatment are important to evaluate, baseline data can be compared with post-treatment testing. The CANS-MCI provides the most staff-efficient, objective, longitudinal assessment of cognitive change available today.

  • Concussion Assessment

    The central changes in cognitive ability due to sports concussion are memory, cognitive processing speed, and reaction time — all measured at millisecond accuracy by the CANS-MCI.  Our automated test also eliminates the potential for the deliberate or unaware bias of in-person testers.

  • Neurological Complications of COVID-19

    Patients who survive COVID-19 are at high risk of neurological decline. The CANS-MCI has been shown to predict both elevated Aβ and tau — both associated with COVID-19 infections.  Our tests capture the most important dimensions for evaluating the cognitive effects of COVID-19.

  • Preclinical Diagnosis of AD

    Biomarker research finds CANS-MCI performance predicts both elevated Aβ and tau.  The CANS-MCI captures item-level response times at millisecond accuracy and can detect patterns of delay associated with the preclinical stage of AD.  To read more about this research, click here.

Professionally evaluated

Results are reviewed and scored by qualified healthcare professionals.

Reliable & valid

Proven accuracy at levels similar to full neuropsychological workups.

Quick

Takes 30 minutes or less, even for those who are impaired.

Timely reports

Comprehensive, easy-to-read reports are sent back to the practice within an hour.

Longitudinal

Useful as a single baseline screen, or for precise evaluation of longitudinal changes.

Predictive

Screens for the earliest stages of all cognitive declines that are predictive of Alzheimer’s and other dementias.

Since 2000, the CANS-MCI has led the way in early detection and awareness of impending dementia.

TELL ME MORE…

Eight distinct tests administered in a single session.

Fair pricing

Unlike current industry norms, pay for tests only after they are performed.

Multilingual

Available in English, Spanish, French and Portuguese

Reimbursable

CPT codes 96132, 96136 and 96137.

No computer skills required

Simple touch screen interactions.  Standardized administration for maximum objectivity and reliability.

Efficient

No clinician resources or time required.

Hearing impaired version

Test questions are audible for hearing patients and readable for the hearing impaired.

TELL ME MORE…

Minimal Hardware Requirements…

 

1

Any Windows operating system


With audio capability, speakers, and video circuitry capable of displaying 640 x 480 resolution with preserved aspect ratio.

 

2

Touchscreen display between 13.3 and 17 inches


For portability and ease-of-use we recommend a “convertible”, “hybrid”, or “2-in-1” notebook / laptop.  Surface Pro tablets (native 2:3 ratio) and point of sale monitors (native 4:3 ratio) are also fine.

 

3

Connection to the Internet


If you don’t have access to the Internet during tests you may upload sessions once you reconnect.
Surface Pro and 2-in-1 hybrid notebook computer

COVID-19 Update

The CANS-MCI test requires only a finger touch on a tablet or computer screen, which can be easily sanitized after every test. The test does not require close proximity of patient and staff, significantly reducing the risk of transmission of Covid-19 or other infectious pathogens.